16,245 Shares in Collegium Pharmaceutical, Inc. (NASDAQ:COLL) Acquired by Sanctuary Advisors LLC

Sanctuary Advisors LLC purchased a new stake in Collegium Pharmaceutical, Inc. (NASDAQ:COLL) during the 2nd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund purchased 16,245 shares of the specialty pharmaceutical company’s stock, valued at approximately $523,000.

Other institutional investors and hedge funds have also recently modified their holdings of the company. Caxton Associates LP acquired a new position in shares of Collegium Pharmaceutical during the 1st quarter valued at $1,730,000. Foundry Partners LLC bought a new position in shares of Collegium Pharmaceutical during the 2nd quarter worth about $492,000. LSV Asset Management grew its stake in shares of Collegium Pharmaceutical by 188.7% in the 1st quarter. LSV Asset Management now owns 380,551 shares of the specialty pharmaceutical company’s stock valued at $14,773,000 after buying an additional 248,751 shares during the period. O Shaughnessy Asset Management LLC grew its stake in shares of Collegium Pharmaceutical by 159.3% in the 1st quarter. O Shaughnessy Asset Management LLC now owns 45,735 shares of the specialty pharmaceutical company’s stock valued at $1,775,000 after buying an additional 28,100 shares during the period. Finally, Vanguard Group Inc. raised its stake in Collegium Pharmaceutical by 0.8% during the 1st quarter. Vanguard Group Inc. now owns 2,330,728 shares of the specialty pharmaceutical company’s stock worth $90,479,000 after buying an additional 17,942 shares during the period.

Wall Street Analysts Forecast Growth

COLL has been the subject of a number of research reports. Needham & Company LLC reissued a “hold” rating on shares of Collegium Pharmaceutical in a research note on Friday, August 9th. HC Wainwright lifted their price target on shares of Collegium Pharmaceutical from $47.00 to $50.00 and gave the company a “buy” rating in a research report on Thursday, September 5th. Piper Sandler restated a “neutral” rating and set a $37.00 price objective on shares of Collegium Pharmaceutical in a report on Friday, October 11th. StockNews.com upgraded shares of Collegium Pharmaceutical from a “buy” rating to a “strong-buy” rating in a report on Tuesday. Finally, Truist Financial upped their target price on shares of Collegium Pharmaceutical from $40.00 to $42.00 and gave the stock a “buy” rating in a report on Friday, August 9th. Two equities research analysts have rated the stock with a hold rating, three have given a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat, the company presently has an average rating of “Moderate Buy” and an average target price of $42.60.

Insider Buying and Selling

In other Collegium Pharmaceutical news, EVP Thomas B. Smith sold 9,593 shares of the business’s stock in a transaction that occurred on Friday, September 13th. The stock was sold at an average price of $36.62, for a total value of $351,295.66. Following the completion of the sale, the executive vice president now owns 53,816 shares in the company, valued at approximately $1,970,741.92. The trade was a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. In other news, EVP Thomas B. Smith sold 9,593 shares of the company’s stock in a transaction dated Friday, September 13th. The shares were sold at an average price of $36.62, for a total transaction of $351,295.66. Following the completion of the transaction, the executive vice president now directly owns 53,816 shares of the company’s stock, valued at approximately $1,970,741.92. This represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, EVP Shirley R. Kuhlmann sold 19,248 shares of the firm’s stock in a transaction dated Thursday, September 5th. The stock was sold at an average price of $38.30, for a total value of $737,198.40. Following the completion of the sale, the executive vice president now directly owns 120,161 shares in the company, valued at $4,602,166.30. The trade was a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. 3.98% of the stock is owned by corporate insiders.

Collegium Pharmaceutical Price Performance

Shares of Collegium Pharmaceutical stock opened at $38.53 on Wednesday. The company has a debt-to-equity ratio of 1.71, a quick ratio of 1.04 and a current ratio of 1.11. Collegium Pharmaceutical, Inc. has a 52-week low of $20.95 and a 52-week high of $42.29. The company has a fifty day moving average of $37.34 and a 200-day moving average of $35.43. The stock has a market capitalization of $1.26 billion, a price-to-earnings ratio of 16.05 and a beta of 0.94.

Collegium Pharmaceutical (NASDAQ:COLL) last posted its quarterly earnings results on Thursday, August 8th. The specialty pharmaceutical company reported $1.62 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.40 by $0.22. The business had revenue of $145.28 million during the quarter, compared to analyst estimates of $143.94 million. Collegium Pharmaceutical had a net margin of 17.32% and a return on equity of 107.62%. The company’s revenue was up 7.2% on a year-over-year basis. During the same period in the prior year, the business posted $1.13 earnings per share. Equities research analysts expect that Collegium Pharmaceutical, Inc. will post 5.79 EPS for the current year.

Collegium Pharmaceutical Company Profile

Collegium Pharmaceutical, Inc, a specialty pharmaceutical company, engages in the development and commercialization of medicines for pain management. Its portfolio includes Xtampza ER, an abuse-deterrent, extended-release, and oral formulation of oxycodone for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment; Nucynta ER and Nucynta IR, which are extended-release and immediate-release formulations of tapentadol, indicated for the management of acute, severe, and persistent pain; Belbuca, a buccal film that contains buprenorphine; and Symproic, an oral formulation of naldemedine for the treatment of opioid-induced constipation in adult patients with chronic non-cancer pain.